Declaration of interests JPF has received research funding (paid to institution) from 89bio, Akero, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Intercept, IONIS, Janssen, Madrigal, Merck, Metacrine, NorthSea Therapeutics, Novartis, Novo Nordisk, Oramed, Pfizer, Poxel, and Sanofi; is involved with advisory boards and consulting for 89bio, Akero, Altimmune, Becton Dickenson, Boehringer Ingelheim, Carmot Therapeutics, Echosens, Eli Lilly, Gilead, Intercept, Merck, Novo Nordisk, Pfizer, and Sanofi; and has received payment or honoraria for speaker bureaus for Eli Lilly. They are seated on the board of directors in T1D Exchange (non-compensated position). SD, LE, and SM are employed at Novo Nordisk and are stockholders of Novo Nordisk shares. FKK has received research grants (paid to institution) from AstraZeneca, Gubra, Novo Nordisk, Sanofi, and Zealand Pharma; and received personal honoraria for consulting, participating in advisory boards, and/or speaking for 89bio, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi, Structure Therapeutics, Zealand Pharma, and Zucara. They are a co-founder and minority shareholder in Antag Therapeutics and co-owner of the medical weight-loss clinic Medicinsk Vægttabsbehandling ApS. IL has received research funding (paid to institution) from Boehringer Ingelheim, Merck, Mylan, Novo Nordisk, Pfizer, and Sanofi. They received advisory/consulting fees and/or other support from AstraZeneca, Bayer, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, GI Dynamics, Intarcia, Intercept, Johnson and Johnson, Mannkind, Merck, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi, Shionogi, Structure Therapeutics, TARGETPharma, Valeritas, and Zealand Pharma. CM has received research funding (paid to institution) from the European Commission, FWO, Helmsley Charitable Trust, JDRF, and Novo Nordisk Foundation. They have received honoraria (paid to institution) for consulting, participating in advisory boards, and/or giving lectures/presentations from ActoBio Therapeutics, AstraZeneca, Avotres, Boehringer Ingelheim, Eli Lilly and Company, Imcyse, Insulet, Mannkind, Medtronic, Novartis, Novo Nordisk, Pfizer, Roche, Sandoz, Sanofi, Vertex, and Zealand Pharma; and are Chair of the Board of Hippo and Friends iVZW, Vice President of EUDF, President of EASD, and Chair of the Board of INNODIA iVZW. SDP acted as consultant, advisory board member, and/or speaker for Abbott, AstraZeneca, Bausch, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, HLS, Janssen, Merck, Novo Nordisk, Pfizer, and Sanofi. They are/have been an investigator in clinical trials funded by AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Pfizer, Prometic, and Sanofi. MD has acted as consultant, advisory board member, and speaker for Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi; an advisory board member for Lexicon, Medtronic, Pfizer, and ShouTi Pharma; and as a speaker for Amgen, AstraZeneca, Napp Pharmaceuticals, and Novartis. MD has received grants in support of investigator and investigator-initiated trials from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, and Sanofi-Aventis.
PubMed
